| Literature DB >> 30941186 |
Jie Liu1, Feng Zhang1, Velagapudi Ravikanth2, Olumayokun A Olajide2, Cen Li3, Li-Xin Wei3.
Abstract
Minerals are alchemically processed as Bhasmas in Ayurvedic medicines or as Zuotai in Tibetan medicines. Ayurveda is a knowledge system of longevity and considers the mineral elixir made from "nature" capable of giving humans perpetual life. Herbo-metallic preparations have a long history in the treatment of various diseases in India, China, and around the world. Their disposition, pharmacology, efficacy, and safety require scientific evaluation. This review discusses the Bhasmas in Ayurvedic medicines and Zuotai in Tibetan medicines for their occurrence, bioaccessibility, therapeutic use, pharmacology, toxicity, and research perspectives. A literature search on Mineral, Bhasma, Ayurvedic medicine, Zuotai, Tibetan medicine, and Metals/metalloids from PubMed, Google and other sources was carried out, and the relevant papers on their traditional use, pharmacology, and toxicity were selected and analyzed. Minerals are processed to form Bhasma or Zuotai to alter their physiochemical properties distinguishing them from environmental metals. The metals found in Ayurveda are mainly from the intentional addition in the form of Bhasma or Zuotai. Bhasma and Zuotai are often used in combination with other herbals and/or animal-based products as mixtures. The advanced technologies are now utilized to characterize herbo-metallic preparations as Quality Assurance/Quality Control. The bioaccessibility, absorption, distribution, metabolism, and elimination of herbo-metallic preparations are different from environmental metals. The pharmacological basis of Bhasma in Ayurveda and Zuotai in Tibetan medicines and their interactions with drugs require scientific research. Although the toxic potentials of Bhasma and Zuotai differ from environmental metals, the metal poisoning case reports, especially lead (Pb), mercury (Hg), and arsenic (As) from inappropriate use of traditional medicines, are increasing, and pharmacovigilance is desired. In risk assessment, chemical forms of metals in Bhasma and Zuotai should be considered for their disposition, efficacy, and toxicity.Entities:
Year: 2019 PMID: 30941186 PMCID: PMC6421027 DOI: 10.1155/2019/1697804
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Examples of preparation and analysis of metals/metalloids in traditional medicines.
|
|
|
|
|
|---|---|---|---|
|
| |||
| Rasasindura | HgS | Kamath et al., 2012 [ | |
| Makardhwaja | HgS, Au | Khedekar et al., 2011 [ | |
| Naga Bhasma | PbS, PbO | Si, Fe, K+ | Nagarajan et al., 2014 [ |
| Tamra Bhasma | CuS | Fe, Mn, Zn, Pb, As, Cd | Jagtap et al., 2012 [ |
| Lauha Kalpas | Fe2O3 | Si, Al, Ca | Gupta et al., 2012 [ |
| Tarakeshwara Rasa | Fe2O3 | SnO2, HgS, SiO2, HgO | Virupaksha & Kumar, 2012 [ |
| Trivanga Bhasma | Sn, Zn, Pb | Hg, Cu, S, Mica | Rasheed et al., 2014 [ |
| Rajata Bhasma | Ag nanoparticles | Sharma et al., 2016 [ | |
| Yashada Bhasma | Zn, ZnO | Umani et al., 2015 [ | |
| Jasad Bhasma | ZnO, ZnS, | HgO | Chavare et al., 2017 [ |
| Vanga bhasma | SnO2 | Kale and Rajurkar, 2018 [ | |
| Praval bhasma | CaO | Mishra et al., 2014 [ | |
| Mica Ash | Silicate minerals | Wijenayakea et al., 2014 [ | |
|
| |||
|
| |||
| Zuotai (Tsothel) | HgS | Fe, Cu, Si, Mg, Ca, Se, K+ | Li et al., 2016 [ |
| Nengchi Bakuang | K(Mg,Fe)3(Al,Fe)Si3O10(OH, F)2 | F, S, Cu, Zn, As, Sn, Ca, P, K | Li et al., 2011 [ |
| KMg3Si3AlO10 (F, OH)2, Mg2SiO4, FeS | |||
| Nengchi Bajin | AuPb2, Ag2S2, PbO, CuS, | PbSO4, NaCu2S2, CaCo3, | Li et al., 2012 [ |
| SiO2, SnS, ZnS | Cu7S4, CaFe2MgC03 | ||
Comparison of frequently used β-HgS and α-HgS in traditional medicines.
|
|
| |
|---|---|---|
| English name | Cinnabar | Metacinnabar |
| Element valence state | Hg2+, S2- | Hg2+, S2- |
| Pressing procedure | grinding and washing | Repeated incinaration |
| Product color | Red | Black |
| Solubility | Insoluble sulfide | Insoluble sulfide |
| Bioaccessibility | Poor | Poor |
| Metabolites | mercuric polysulfide | mercuric polysulfide |
| TCM name | Zhusha | Zuotai (gTsothal) |
| In Tibetan and Chinese |
|
|
| In Ayurvedic medicine |
|
|
Examples of evaluation of toxicity in metal-containing traditional medicines.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| HgS, HgCl2, MeHg, As3+, As5+ | Cell cultures | Cytotoxciity | HgS < < HgCl2 < MeHg | [ |
| MTT assay | As4S4< < As3+< As5+ | |||
|
| ||||
|
| ||||
| Lauha Bhasma | Acute 14-d study in rats | Mortality | No acute mortality up to 100 TD | [ |
| Arogyavardhini vati | 28-d study in rats | Neurotoxicity | Arogyavardhini < HgCl2 | [ |
| Liver and kidney toxicity, GSH, MDA | Arogyavardhini vati < HgCl2 | |||
| Energic-31 capsule | 28-d study in rats | Learning and memory function | Energic-31 < < HgCl2, Pb, Cd, As | [ |
| Brain MDA and GSH | ||||
| Brain metal accumulation | ||||
| Calcury tablet | 28-d study in rats | Calcury < < HgCl2, Pb, Cd, As | ||
| Cinnabar (HgS) | 14-d study in rats | Neurotoxicity, Na+/K+ ATPase | Cinnabar (1 g/kg) << MeHg (2 mg/kg) | [ |
| Hg accumulation | ||||
|
| ||||
|
| ||||
| Tamra (copper) bhasma | 45-d study in rats | Serology and histopathology | Shodhita Tamra < Ashodhita Tamra | [ |
| Trivanga Bhasma | 90-d study in mice | Serology and histopathology | No overt injury at 1, 5, 10 TD | [ |
| Zuotai (gTso thal) | 135-d study in mice | No abnormality in serology and morphology | [ | |
| Hg accumulation increased but reversible | ||||
|
| ||||
|
| ||||
| Cinnabar | Weanling nice (7 weeks) | Developmental and neuro-toxicity | Cinnabar << HgCl2 or MeHg | [ |
| Zuotai (gTso thal) | Weanling and old mice (7-d) | Old mice is more susceptible to Hg toxicity | Zuotai << HgCl2, MeHg | [ |
Figure 1An illustration of herb-metallic preparations and the research needs.